ArticleFrontiers in oncology2023

Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.

Tianyuan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.